PMID- 32518777
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 8
IP  - 10
DP  - 2020 May 26
TI  - Ligliptin for treatment of type 2 diabetes mellitus with early renal injury: 
      Efficacy and impact on endogenous hydrogen sulfide and endothelial function.
PG  - 1878-1886
LID - 10.12998/wjcc.v8.i10.1878 [doi]
AB  - BACKGROUND: Diabetes is a clinically common chronic disease, and its incidence 
      has been increasing in recent years. Diabetes is believed to accelerate the 
      process of atherosclerosis in patients, and abnormal endothelial function is an 
      important factor leading to diabetic kidney damage. AIM: To investigate the 
      efficacy of ligliptin in the treatment of type 2 diabetes mellitus (T2DM) with 
      early renal injury and its effect on serum endogenous hydrogen sulfide (H(2)S), 
      endothelial cell particles, and endothelial function. METHODS: From January 2018 
      to April 2019, 110 patients with T2DM and early kidney injury treated at our 
      hospital were divided into an observation group (receiving ligliptin treatment, n 
      = 54) and a control group (receiving gliquidone therapy, n = 56). Blood glucose 
      and renal function before and after treatment were compared between the two 
      groups. RESULTS: The differences in fasting blood glucose, 2 h blood glucose, and 
      glycated hemoglobin were not statistically significant between the two groups 
      after treatment. The urinary albumin excretion rate after treatment in the 
      ligliptin group was 70.32 +/- 11.21 microg/min, which was significantly lower than that 
      of the gliquidone group (P = 0.000). Serum endogenous H(2)S and endothelial cell 
      microparticles of the ligliptin treatment group were 40.04 +/- 8.82 mol/L and 
      133.40 +/- 34.39, respectively, which were significantly lower than those of the 
      gliquidone treatment group (P = 0.000 for both); endothelin-dependent diastolic 
      function and nitric oxide after treatment in the ligliptin group were 7.98% +/- 
      1.22% and 190.78 +/- 30.32 mol/L, significantly higher than those of the gliquidone 
      treatment group (P = 0.000 for both). CONCLUSION: Ligliptin treatment of T2DM 
      with early renal injury has the same glucose-lowering effect as gliquidone 
      treatment. Ligliptin treatment has a better effect and it can significantly 
      improve the renal function and vascular endothelial function of patients, and 
      reduce serum endogenous H(2)S and endothelial cell particle levels.
CI  - (c)The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Zhang, Jian
AU  - Zhang J
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan 250012, 
      Shandong Province, China.
FAU - Du, Yong-Li
AU  - Du YL
AD  - Department of Pharmacy, Tai'an Central Hospital, Tai'an 271000, Shandong 
      Province, China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - Department of Rheumatology, Tai'an Central Hospital, Tai'an 271000, Shandong 
      Province, China.
FAU - Sui, Hong
AU  - Sui H
AD  - Department of Geriatrics, Tai'an Central Hospital, Tai'an 271000, Shandong 
      Province, China.
FAU - Hou, Wei-Kai
AU  - Hou WK
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan 250012, 
      Shandong Province, China. pro.hwk@163.com.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC7262708
OTO - NOTNLM
OT  - Early renal injury
OT  - Endothelial cell granules
OT  - Endothelial function
OT  - Ligliptin
OT  - Serum endogenous hydrogen sulfide
OT  - Type 2 diabetes
COIS- Conflict-of-interest statement: All authors declare no conflicts of interest 
      related to this article.
EDAT- 2020/06/11 06:00
MHDA- 2020/06/11 06:01
PMCR- 2020/05/26
CRDT- 2020/06/11 06:00
PHST- 2020/01/20 00:00 [received]
PHST- 2020/03/19 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/06/11 06:00 [entrez]
PHST- 2020/06/11 06:00 [pubmed]
PHST- 2020/06/11 06:01 [medline]
PHST- 2020/05/26 00:00 [pmc-release]
AID - 10.12998/wjcc.v8.i10.1878 [doi]
PST - ppublish
SO  - World J Clin Cases. 2020 May 26;8(10):1878-1886. doi: 10.12998/wjcc.v8.i10.1878.